New York A 6475: Requires health insurance policies to cover comprehensive genetic screening for ovarian and prostate cancers

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
A06475 Summary:

BILL NOA06475 

&nbsp

SAME ASNo Same As

&nbsp

SPONSORSeptimo

&nbsp

COSPNSR

&nbsp

MLTSPNSR

&nbsp

Amd §§3216, 3221 & 4303, Ins L

&nbsp

Requires health insurance policies to cover comprehensive genetic screening and FDA approved biomarker testing for ovarian and prostate cancers.

Go to top A06475 Actions:

BILL NOA06475 

&nbsp

03/05/2025referred to insurance

01/07/2026referred to insurance

Go to topA06475 Committee&nbspVotes:

Go to topA06475 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topA06475 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 6475

 2025-2026 Regular Sessions

 IN ASSEMBLY

 March 5, 2025
 ___________

 Introduced by M. of A. SEPTIMO -- read once and referred to the Commit-
 tee on Insurance

 AN ACT to amend the insurance law, in relation to requiring health
 insurance policies to fully cover comprehensive genetic testing and
 FDA approved biomarker testing for ovarian and prostate cancers

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. This act shall be known and may be cited as the "Ana Lucia
 2 act".
 3 § 2. Paragraph 11-a of subsection (i) of section 3216 of the insurance
 4 law is amended by adding a new subparagraph (C) to read as follows:
 5 (C) (i) Such policy shall provide additional full coverage for compre-
 6 hensive genetic testing and FDA approved testing based on family or
 7 person's history for prostatic and ovarian cancer when recommended by a
 8 doctor, a board-certified geneticist or a board-certified genetic coun-
 9 selor. Such coverage shall also be provided after the patient's initial
 10 diagnosis. Patients need to know if they carry the genetic or inheri-
 11 tance mutation, which can help to determine possible treatments. Genetic
 12 screening shall be covered for prostate and ovarian cancer patients'
 13 family members. The genetic result shall not be used against family
 14 members that carry the genetic or inheritance mutation for insurance
 15 coverage purposes.
 16 (ii) All costs associated with such additional full coverage shall not
 17 be subject to annual deductibles and coinsurance but shall be borne
 18 solely by the insurer.
 19 § 3. Paragraph 11-a of subsection (l) of section 3221 of the insurance
 20 law is amended by adding a new subparagraph (C) to read as follows:
 21 (C)(i) Such policy shall provide additional full coverage for compre-
 22 hensive genetic testing and FDA approved testing based on family or
 23 person's history for prostatic and ovarian cancer when recommended by a
 24 doctor, a board-certified geneticist or a board-certified genetic coun-

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD07098-01-5

 A. 6475 2

 1 selor. Such coverage shall also be provided after the patient's initial
 2 diagnosis. Patients need to know if they carry the genetic or inheri-
 3 tance mutation, which can help to determine possible treatments. Genetic
 4 screening shall be covered for prostate and ovarian cancer patients'
 5 family members. The genetic result shall not be used against family
 6 members that carry the genetic or inheritance mutation for insurance
 7 coverage purposes.
 8 (ii) All costs associated with such additional full coverage shall not
 9 be subject to annual deductibles and coinsurance but shall be borne
 10 solely by the insurer.
 11 § 4. Subsection (z-1) of section 4303 of the insurance law is amended
 12 by adding a new paragraph 3 to read as follows:
 13 (3)(A) Such policy shall provide additional full coverage for compre-
 14 hensive genetic testing and FDA approved testing based on family or
 15 person's history for prostatic and ovarian cancer when recommended by a
 16 doctor, a board-certified geneticist or a board-certified genetic coun-
 17 selor.
 18 (B) All costs associated with such additional full coverage shall not
 19 be subject to annual deductibles and coinsurance but shall be borne
 20 solely by the insurer. Such coverage shall also be provided after the
 21 patient's initial diagnosis. Patients need to know if they carry the
 22 genetic or inheritance mutation, which can help to determine possible
 23 tre